Page last updated: 2024-11-12
fluorapacin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
fluorapacin: has antineoplastic activity; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 11638228 |
CHEMBL ID | 215685 |
SCHEMBL ID | 1740610 |
MeSH ID | M0520646 |
Synonyms (15)
Synonym |
---|
CHEMBL215685 |
SCHEMBL1740610 |
fluorapacin |
AKOS030228713 |
bis(4-fluorobenzyl)trisulfide |
AS-63498 |
bis[(4-fluorophenyl)methyl]trisulfane |
869811-23-4 |
bis[(4-fluorophenyl)methyl] trisulfide |
1,3-bis(4-fluorobenzyl)trisulfane |
trisulfide, bis((4-fluorophenyl)methyl) |
1-fluoro-4-((4-fluorophenyl)methylsulfanyldisulfanylmethyl)benzene |
unii-t47ns4w7uk |
t47ns4w7uk , |
1-fluoro-4-[[(4-fluorophenyl)methyltrisulfanyl]methyl]benzene |
Research Excerpts
Dosage Studied
Excerpt | Relevance | Reference |
---|---|---|
"9% (mean+/-SE, n=6) of dosage after 48h of administration." | ( Identification and simultaneous determination of p-FHA and p-FBA, two metabolites of anti-tumor agent--Fluorapacin in rat urine. An, H; Jiang, H; Pan, H; Xu, X; Zeng, S; Zhou, H, 2009) | 0.57 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (51)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1214953 | Drug metabolism in Sprague-Dawley rat RBC assessed as p-FBA metabolite formation at slow rate at 50 uM by HPLC analysis | 2013 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5 | Metabolism of bis(4-fluorobenzyl)trisulfide and its formation of hemoglobin adduct in rat erythrocytes. |
AID1214936 | Drug level in Sprague-Dawley rat RBC treated with p-FBM by HPLC analysis | 2013 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5 | Metabolism of bis(4-fluorobenzyl)trisulfide and its formation of hemoglobin adduct in rat erythrocytes. |
AID1214932 | Drug metabolism in Sprague-Dawley rat RBC assessed as p-FBA metabolite formation by HPLC analysis | 2013 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5 | Metabolism of bis(4-fluorobenzyl)trisulfide and its formation of hemoglobin adduct in rat erythrocytes. |
AID1214935 | Drug level in Sprague-Dawley rat RBC treated with BFBDS by HPLC analysis | 2013 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5 | Metabolism of bis(4-fluorobenzyl)trisulfide and its formation of hemoglobin adduct in rat erythrocytes. |
AID270896 | Antitumor activity against human HT1080 cell line by RTCES assay | 2006 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18 | Synthesis and anti-tumor evaluation of new trisulfide derivatives. |
AID270898 | Antitumor activity against human MCF7 cell line by RTCES assay | 2006 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18 | Synthesis and anti-tumor evaluation of new trisulfide derivatives. |
AID1214943 | Binding affinity to hemoglobin in Sprague-Dawley rat RBC assessed as compound-derived glutathionylation of beta globin chain of hemoglobin at >250 uM after 30 mins by ESI/MS analysis | 2013 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5 | Metabolism of bis(4-fluorobenzyl)trisulfide and its formation of hemoglobin adduct in rat erythrocytes. |
AID270897 | Antitumor activity against human H460 cell line by RTCES assay | 2006 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18 | Synthesis and anti-tumor evaluation of new trisulfide derivatives. |
AID1214965 | In vivo binding affinity to hemoglobin in Sprague-Dawley rat blood assessed as compound-derived hemoglobin adduct formation at 50 mg/kg, iv administered as single dose after 30 mins by ESI/MS analysis | 2013 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5 | Metabolism of bis(4-fluorobenzyl)trisulfide and its formation of hemoglobin adduct in rat erythrocytes. |
AID1214917 | Drug metabolism in phosphate buffered saline assessed as p-FBM metabolite formation at 5 uM by HPLC analysis in presence of N-acetyl cysteine | 2013 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5 | Metabolism of bis(4-fluorobenzyl)trisulfide and its formation of hemoglobin adduct in rat erythrocytes. |
AID1214951 | Drug recovery in Sprague-Dawley rat RBC at 64 uM after 2 hrs by HPLC analysis | 2013 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5 | Metabolism of bis(4-fluorobenzyl)trisulfide and its formation of hemoglobin adduct in rat erythrocytes. |
AID1214954 | Half life in Sprague-Dawley rat diluted RBC at 25 uM by HPLC analysis | 2013 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5 | Metabolism of bis(4-fluorobenzyl)trisulfide and its formation of hemoglobin adduct in rat erythrocytes. |
AID1214947 | Drug metabolism in Sprague-Dawley rat whole blood assessed as p-FBA metabolite formation at 50 uM by UPLC-MS/MS analysis | 2013 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5 | Metabolism of bis(4-fluorobenzyl)trisulfide and its formation of hemoglobin adduct in rat erythrocytes. |
AID1214963 | Binding affinity to hemoglobin in Sprague-Dawley rat RBC assessed as compound-modified Cys93-containing bet1/2/3/4 globin chain of hemoglobin at 500 uM by tryptic digestion based LC-MS/MS analysis | 2013 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5 | Metabolism of bis(4-fluorobenzyl)trisulfide and its formation of hemoglobin adduct in rat erythrocytes. |
AID1214924 | Stability of compound in phosphate buffered saline at 5 uM after 30 mins by HPLC analysis in presence of cysteine | 2013 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5 | Metabolism of bis(4-fluorobenzyl)trisulfide and its formation of hemoglobin adduct in rat erythrocytes. |
AID1214961 | Binding affinity to hemoglobin in Sprague-Dawley rat RBC assessed as compound-modified Cys125-containing beta2/3 globin chain of hemoglobin at 250 uM by tryptic digestion based LC-MS/MS analysis | 2013 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5 | Metabolism of bis(4-fluorobenzyl)trisulfide and its formation of hemoglobin adduct in rat erythrocytes. |
AID1214937 | Drug level in Sprague-Dawley rat RBC treated with p-FBA by HPLC analysis | 2013 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5 | Metabolism of bis(4-fluorobenzyl)trisulfide and its formation of hemoglobin adduct in rat erythrocytes. |
AID1214918 | Drug metabolism in phosphate buffered saline assessed as p-FBM metabolite formation at 5 uM by HPLC analysis in presence of coenzyme A | 2013 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5 | Metabolism of bis(4-fluorobenzyl)trisulfide and its formation of hemoglobin adduct in rat erythrocytes. |
AID1214916 | Drug metabolism in phosphate buffered saline assessed as p-FBM metabolite formation at 5 uM by HPLC analysis in presence of cysteine | 2013 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5 | Metabolism of bis(4-fluorobenzyl)trisulfide and its formation of hemoglobin adduct in rat erythrocytes. |
AID1214962 | Binding affinity to hemoglobin in Sprague-Dawley rat RBC assessed as compound-modified Cys104/Cys111-containing alpha1 globin chain of hemoglobin at 500 uM by tryptic digestion based LC-MS/MS analysis | 2013 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5 | Metabolism of bis(4-fluorobenzyl)trisulfide and its formation of hemoglobin adduct in rat erythrocytes. |
AID1214949 | Drug recovery in Sprague-Dawley rat whole blood at 64 uM after 2 hrs by HPLC analysis | 2013 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5 | Metabolism of bis(4-fluorobenzyl)trisulfide and its formation of hemoglobin adduct in rat erythrocytes. |
AID1214939 | Drug metabolism in Sprague-Dawley rat whole blood assessed as p-FBM metabolite formation by HPLC analysis | 2013 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5 | Metabolism of bis(4-fluorobenzyl)trisulfide and its formation of hemoglobin adduct in rat erythrocytes. |
AID270894 | Antitumor activity against human A2780 cell line by RTCES assay | 2006 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18 | Synthesis and anti-tumor evaluation of new trisulfide derivatives. |
AID270901 | Antitumor activity against human HepG2 cell line by RTCES assay | 2006 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18 | Synthesis and anti-tumor evaluation of new trisulfide derivatives. |
AID1214928 | Drug metabolism in phosphate buffered saline assessed as GSH-p-FBM metabolite formation at 5 uM after 30 mins by LC-MS analysis in presence of GSH | 2013 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5 | Metabolism of bis(4-fluorobenzyl)trisulfide and its formation of hemoglobin adduct in rat erythrocytes. |
AID270893 | Antitumor activity against human jurkat cell line by MTT assay | 2006 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18 | Synthesis and anti-tumor evaluation of new trisulfide derivatives. |
AID1214957 | Drug metabolism in phosphate buffered saline assessed as BFBDS metabolite formation at 5 uM by HPLC analysis in presence of cysteine | 2013 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5 | Metabolism of bis(4-fluorobenzyl)trisulfide and its formation of hemoglobin adduct in rat erythrocytes. |
AID1214940 | Drug metabolism in Sprague-Dawley rat whole blood assessed as p-FBA metabolite formation by HPLC analysis | 2013 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5 | Metabolism of bis(4-fluorobenzyl)trisulfide and its formation of hemoglobin adduct in rat erythrocytes. |
AID1214915 | Drug metabolism in phosphate buffered saline assessed as p-FBM metabolite formation at 5 uM by HPLC analysis in presence of GSH | 2013 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5 | Metabolism of bis(4-fluorobenzyl)trisulfide and its formation of hemoglobin adduct in rat erythrocytes. |
AID270895 | Antitumor activity against human OVACR4 cell line by RTCES assay | 2006 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18 | Synthesis and anti-tumor evaluation of new trisulfide derivatives. |
AID1214952 | Drug metabolism in Sprague-Dawley rat RBC assessed as rapid p-FBM metabolite formation at 50 uM by HPLC analysis | 2013 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5 | Metabolism of bis(4-fluorobenzyl)trisulfide and its formation of hemoglobin adduct in rat erythrocytes. |
AID1214968 | Drug metabolism in Sprague-Dawley rat whole blood assessed as BFBDS metabolite formation at 50 uM by GC/MS analysis | 2013 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5 | Metabolism of bis(4-fluorobenzyl)trisulfide and its formation of hemoglobin adduct in rat erythrocytes. |
AID1214938 | Drug metabolism in Sprague-Dawley rat whole blood assessed as BFBDS metabolite formation by HPLC analysis | 2013 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5 | Metabolism of bis(4-fluorobenzyl)trisulfide and its formation of hemoglobin adduct in rat erythrocytes. |
AID1214926 | Stability of compound in phosphate buffered saline at 5 uM after 30 mins by HPLC analysis in presence of coenzyme A | 2013 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5 | Metabolism of bis(4-fluorobenzyl)trisulfide and its formation of hemoglobin adduct in rat erythrocytes. |
AID1214944 | Binding affinity to hemoglobin in Sprague-Dawley rat RBC assessed as compound-derived hemoglobin adduct formation at <250 uM after 30 mins by ESI/MS analysis | 2013 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5 | Metabolism of bis(4-fluorobenzyl)trisulfide and its formation of hemoglobin adduct in rat erythrocytes. |
AID1214942 | Binding affinity to hemoglobin in Sprague-Dawley rat RBC assessed as compound-derived monoadduct formation on both alpha1 and beta2 globin chain of hemoglobin at >250 uM after 30 mins by ESI/MS analysis | 2013 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5 | Metabolism of bis(4-fluorobenzyl)trisulfide and its formation of hemoglobin adduct in rat erythrocytes. |
AID1214955 | Half life in Sprague-Dawley rat diluted RBC at 1 uM by HPLC analysis | 2013 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5 | Metabolism of bis(4-fluorobenzyl)trisulfide and its formation of hemoglobin adduct in rat erythrocytes. |
AID1214923 | Stability of compound in phosphate buffered saline at 5 uM after 30 mins by HPLC analysis in presence of GSH | 2013 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5 | Metabolism of bis(4-fluorobenzyl)trisulfide and its formation of hemoglobin adduct in rat erythrocytes. |
AID1214960 | Binding affinity to hemoglobin in Sprague-Dawley rat RBC assessed as compound-modified Cys104/Cys111-containing alpha1 globin chain of hemoglobin at 250 uM by tryptic digestion based LC-MS/MS analysis | 2013 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5 | Metabolism of bis(4-fluorobenzyl)trisulfide and its formation of hemoglobin adduct in rat erythrocytes. |
AID1214925 | Stability of compound in phosphate buffered saline at 5 uM after 30 mins by HPLC analysis in presence of N-acetyl cysteine | 2013 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5 | Metabolism of bis(4-fluorobenzyl)trisulfide and its formation of hemoglobin adduct in rat erythrocytes. |
AID1214956 | Drug metabolism in phosphate buffered saline assessed as BFBDS metabolite formation at 5 uM by HPLC analysis in presence of GSH | 2013 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5 | Metabolism of bis(4-fluorobenzyl)trisulfide and its formation of hemoglobin adduct in rat erythrocytes. |
AID1214931 | Drug metabolism in Sprague-Dawley rat RBC assessed as p-FBM metabolite formation by HPLC analysis | 2013 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5 | Metabolism of bis(4-fluorobenzyl)trisulfide and its formation of hemoglobin adduct in rat erythrocytes. |
AID1214927 | Stability in Sprague-Dawley rat RBC at 5 uM incubated for 1 hr after 5 mM thiol residue blocking agent iodoacetamide challenge by HPLC analysis | 2013 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5 | Metabolism of bis(4-fluorobenzyl)trisulfide and its formation of hemoglobin adduct in rat erythrocytes. |
AID1214950 | Drug recovery in Sprague-Dawley rat plasma at 64 uM after 2 hrs by HPLC analysis | 2013 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5 | Metabolism of bis(4-fluorobenzyl)trisulfide and its formation of hemoglobin adduct in rat erythrocytes. |
AID1214958 | Drug metabolism in phosphate buffered saline assessed as BFBDS metabolite formation at 5 uM by HPLC analysis in presence of N-acetyl cysteine | 2013 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5 | Metabolism of bis(4-fluorobenzyl)trisulfide and its formation of hemoglobin adduct in rat erythrocytes. |
AID1214959 | Drug metabolism in phosphate buffered saline assessed as BFBDS metabolite formation at 5 uM by HPLC analysis in presence of coenzyme A | 2013 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5 | Metabolism of bis(4-fluorobenzyl)trisulfide and its formation of hemoglobin adduct in rat erythrocytes. |
AID270899 | Antitumor activity against human M231 cell line by RTCES assay | 2006 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18 | Synthesis and anti-tumor evaluation of new trisulfide derivatives. |
AID270900 | Antitumor activity against human HeLa cell line by RTCES assay | 2006 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18 | Synthesis and anti-tumor evaluation of new trisulfide derivatives. |
AID1214930 | Drug metabolism in Sprague-Dawley rat RBC assessed as BFBDS metabolite formation by HPLC analysis | 2013 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5 | Metabolism of bis(4-fluorobenzyl)trisulfide and its formation of hemoglobin adduct in rat erythrocytes. |
AID1214969 | Drug metabolism in Sprague-Dawley rat whole blood assessed as p-FBM metabolite formation at 50 uM by GC/MS analysis | 2013 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5 | Metabolism of bis(4-fluorobenzyl)trisulfide and its formation of hemoglobin adduct in rat erythrocytes. |
AID1214964 | Binding affinity to hemoglobin in Sprague-Dawley rat RBC assessed as compound-modified Cys125-containing bet1/2/3 globin chain of hemoglobin at 500 uM by tryptic digestion based LC-MS/MS analysis | 2013 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5 | Metabolism of bis(4-fluorobenzyl)trisulfide and its formation of hemoglobin adduct in rat erythrocytes. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (10)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 9 (90.00) | 29.6817 |
2010's | 1 (10.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 11.85
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.85) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 10 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |